The Federal Circuit continues to be flooded with petitions to
revisit its panel decision in Arthrex, Inc. v.
Smith & Nephew, Inc., 941 F.3d 1320, No. 2018-2140
(Fed. Cir. 2019). As previously
discussed, all three parties in Arthrex filed
petitions for en banc rehearing—and those petitions
remain pending. Parties in other cases also have asked the full
Court to address issues related to Arthrex. See
e.g., Bedgear, LLC v. Fredman Bros. Furniture Company,
Inc., No. 2018-2082 (petition filed Jan. 8); Customedia
Technologies, LLC v. Dish Network Corp., No. 2019-1001
(petition filed Jan. 7); Sanofi-Aventis Deutschland v. Mylan
Pharmaceuticals Inc., No. 2019-1368 (petitions filed Dec. 19
& 20); Duke University v. BioMarin Pharmaceutical
Inc., No. 2018-1696 (petition filed Dec. 11).